ADF Awards

The ADF announces various prizes to reward scientists / researchers from the field of dermatological research. In addition to the Paul Langerhans Award for established researchers and the Egon Macher Award for young investigators outstanding works in the field of allergy research (ADF / ECARF Award of European Allergy Research) and oncology (Dermato Oncology Junior Scientist Award) will be honored on the ADF Annual Meetings.

In addition, the best posters will be awarded with a poster prize.

For the complete tender texts and the detailed allocation policies please click on the highlighted link.

Please note:
For poster prices, the ADF / ECARF Award for European Allergy Research, the Dermato Oncology Junior Scientist Awards and for the Translational Research Award, a separate application is not necessary. For these prices all abstracts submitted before the deadline will be evaluated.
Submissions for the Paul Langerhans Award and the Egon Macher Award should be made in all cases exclusively in electronic form as one PDF file to the ADF office.
Submission deadline: November 01.


Dermato Oncology Junior Scientist Award of the ADF

- Supported by the Erwin + Irmgard-Egner Foundation -

In the year 2024 the ADF is able to announce 5 awards for junior scientists working in the field of Dermato Oncology. These awards are support by the Erwin & Irmgard Egner foundation (two Junior Scientist Awards). 
All studies submitted in time to the ADF annual meeting (poster / oral presentation) with a focus in the field of oncology will be considered. The award will be given to the first author or a working group that conducted the research. The allocation of the award is independent of the ADF membership of the authors. 

The award is endowed with 2.500 € dotiert.

The award ceremony will be held during the Annual ADF meeting. The awardee will be chosen by an independent board of trustees that is elected by the ADF board every three years.

The awardee is asked to publish a short report at the ADF home journal Experimental Dermatology.

Board of trustees:

  • Prof. Dr. rer. nat. Patrizia Stoitzner (Chair)
  • Prof. Dr. med. Tobias Bald
  • Prof. Dr. med. Christoffer Gebhardt
  • Prof. Dr. rer. nat. Iris Helfrich
  • Prof. Dr. med. Jan Nicolay
  • Prof. Dr. med. Carsten Weishaupt

Past awardees of the Dermato Oncology Junior Scientist Award of the ADF

Simona Saluzzo, Vienna
P168: A subsets of skin resident CD8+ T cells protects organ transplant receivers from skin cancer development

Saskia Vadder, Bonn
P190: The Influence of Nras and Trp53 Point Mutations on Melanoma Plasticity and the Tumor Microenvironment

Mette Purde, St. Gallen
P204: Propagating viral vector-based vaccine platform as potent therapeutic strategy for solid tumor elimination

Luiza Martins Nascentes Melo, Essen
P209: Selenoprotein O regulates melanoma metastasis through mitochondrial complex II activity

Luisa Bopp, Cologne
P214: Metabolite-driven regulation of T cells in human keratinocyte-derived skin cancer

Sheena. Daignault-Mill, Woolloongabba
P211: Overcoming Immune Checkpoint Inhibitor Resistance to Improve Melanoma Therapy

Florian Hornsteiner, Innsbruck
P200: The role of dendritic cells in tumor-targeted therapy mediated anti-tumor immunity

Anthony Buzzai, Magdeburg
P108: Tumour-specific CD4+ T cells recruit inflammatory monocytes that acquire IFN-activated functions to control immune evasive tumours

Corinne Huebers, Mannheim
P209: nAngiopoietin-like 4 inhibits metastasis formation

Jan-Malte Placke, Essen
P199: Inhibition of the mTOR inhibitory protein sirtuin 1 leads to faster tumor growth under PD1-based immune checkpoint blockade

Yuanyuan Wang, Hamburg
P191: Heparan sulfate dependent binding of melanoma cells to plasmatic von Willebrand factor attenuates melanoma metastasis

Fang Zhao, Essen
P102: Profiling of tumor-infiltrating T cells for guidance of melanoma salvage therapy in immune-checkpoint-blockade resistant patients

Dennis Gerloff
P213: Melanoma derived extracellular vesicles deliver miRNAs as molecular switches in macrophage activation

No Award

Alexander Thiem, Würzburg
P186: p53 is involved in basal and IFN-gamma induced PD-L1 expression in melanoma

Corinna Kosnopfel, Tübingen
P198: Inhibition of RSK family members can effectively target malignant melanoma cells with MAPK pathway hyperactivation

Agnes Forsthuber, Wien
A dual role of neutrophils in cutaneous melanoma

Bianca Simon, Erlangen
The simultaneous siRNA-mediated downregulation of PD-1 and CTLA-4 to improve CAR-T cell immunotherapy of melanoma

Naveen Shridhar, Bonn
Effect of selective Gq/11-inhibition on malignant melanoma

York Kamenisch/Tarza Baban, Regensburg
Ultraviolet (UV)-A irradiation induces melanoma invasion via enhanced Warburg effect

Oana-Diana Persa, Cologne
Dual role of aPKC/ in skin carcinogenesis

Mirko Gries, Heidelberg
Damage-associated molecular pattern molecules as novel predictive markers in melanoma treatment with immune checkpoint inhibitors

Ellen Brenner, Tübingen
Stat1-induced cancer cell senescence protects from metastases

Stefanie Riesenberg, Bonn
MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment

Christian Posch, Wien
Phospho-proteomic analysis reveals increased CK2alpha kinase activity in NRAS(Q61) mutant melanoma

Katharina Amschler, Göttingen
Melanoma cells adapt flexibly to variation of N- and E-cadherin-density on the nanoscale

Heike Niessner, Tuebingen
The BRAF inhibitor LGX818 (encorafenib) induces endoplasmic reticulum stress and sensitizes NRAS-mutant melanoma cells to the MEK inhibitor binimetinib

Bastian Schilling/Klaus Griewank, Essen
Dual immune checkpoint blockage delays GNAQ-driven tumor growth in an autologous murine uveal melanoma model

Andrea Tuettenberg, Mainz
Molecules associated with T regulatory cell function are highly expressed on melanoma: Novel targets for immunotherapeutic strategies (P133)

Nanoparticular targeting of tolerance inducing macrophages, DC and myeloid suppressor cells - new strategies for therapeutic approaches in immune-mediated diseases (P154)

Tobias Sinnberg, Tuebingen
Hypoxia confers resistance towards ascorbate-induced ROS-driven cytotoxicity in melanoma cell lines (P286)

Canonical Wnt signalling enhances neural crest migration in zebrafish and epithelial mesenchymal transition associated melanoma cell invasion (P289)

Beta-catenin in the course of aquired resistance to the BRAFV600E inhibitor vemurafenib in malignant melanoma (P291)

Amir Yazdi, Tuebingen (Nachwuchspreis)
Contrasting, cell type-specific role of ASC in epithelial skin cancer

Iris Helfrich, Essen (Nachwuchspreis)
Neuropilin-1 deficiency on CD4+Foxp3+ regulatory T cells impaires tumor growth in melanoma

Johanna Kaufmann, Heidelberg (Nachwuchspreis)
Specific killing of melanoma cells by infection with an oncolytic measles virus directed to the surface antigen HMWMAA

Maria Feoktistova und Peter Geserick, Mannheim (Nachwuchspreis)
The Ripoptosome - a novel molecular complex differentially regulated by cFLIP isoforms and a critical switch between apoptotic and necroptotic cell death in skin tumor cells

Carola Berking, Munich (Hauptpreis)
Molekulare Mechanismen beim malignen Melanom

Jenny Landsberg, Bonn (Nachwuchspreis)
T cell mediated immune surveillance promotes melanoma cell dedifferentiation in the genetically engineered Hgf-Cdk4R24C mouse model

Christian Busch, Tuebingen (Nachwuchspreis)
Bone morphogenetic protein and nodal regulate adhesion and migration in melanoma cells and confer a malignant phenotype to melanocytes in vitro and in vivo

AG Birgit Schittek, Tuebingen (Hauptpreis)
Molekulare Mechanismen der Melanomentstehung

Sebastian Haferkamp, Wuerzburg (Nachwuchspreis)
Oncogene-induced senescence of primary human melanocyte

Silke Kuphal, Regensburg (Nachwuchspreis)
Persistent NFkappaB activation in malignant melanoma is generated through loss of the tumor suppressor CYLD

AG Juergen Eberle, Berlin

Petra Boukamp, Heidelberg

Selma Ugurel-Becker, Wuerzburg

Erwin S. Schultz, Marburg